Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913

Introduction In preclinical data, the combination therapy with S-1 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) had a synergistic antitumor effect on non-small cell lung cancer (NSCLC), regardless of the EGFR mutation status. Patients and Methods Patients with previous...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Invest New Drugs
Главные авторы: Nakahara, Yoshiro, Shimokawa, Tsuneo, Misumi, Yuki, Nogami, Naoyuki, Shinkai, Tetsu, Seki, Nobuhiko, Hosomi, Yukio, Hida, Naoya, Okamoto, Hiroaki
Формат: Artigo
Язык:Inglês
Опубликовано: Springer US 2020
Предметы:
Phase II Studies
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7851018/
https://ncbi.nlm.nih.gov/pubmed/32803700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00985-4
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы